Skip to main content
MIRM
NASDAQ Life Sciences

Mirum Lifts 2026 Sales Guidance to $715-720M After Q3 Revenue Jump to $185.7M

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$87.03
Mkt Cap
$5.651B
52W Low
$63.232
52W High
$130
52W Position info
38% above low
Off High info
33% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MIRM sits 38% above its 52-week low of $63.232.

Summary

Mirum raised full-year net product sales guidance to $715-720 million after Q3 product sales came in at $185.7 million versus $133.0 million a year earlier. LIVMARLI drove $133.4 million of that, up 45% year-over-year, with Bile Acid Medicines adding $52.3 million, up 28%. The quarter still produced a net loss of $40.8 million, or $0.62 per basic share, as operating expenses climbed to $245.5 million from $130.4 million, including $42.1 million of brelovitug development spend and $13.5 million of acquired IPR&D. This follows the September FDA approval and launch of ATEBRIOZ in FOP and the positive AZURE-1 and EXPAND Phase 3 readouts, which management framed as the base for five potential upcoming approvals and label expansions. Balance sheet shows $500.5 million in cash and investments, and the company retired $20.0 million of its 4.00% convertible notes due 2029, roughly a quarter of the outstanding issue. Next hard data point is AZURE-4 Phase 3 topline in Q4 2026, with full AZURE-1 results due at The Liver Meeting on November 8.

At the time of this announcement, MIRM was trading at $87.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

MIRM - Latest Insights

MIRM
Nov 10, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $93.18
Real-time Price: $96.13 info
Change: +$2.95 (+3%) info
Market Cap: $6.276B info
MIRM
Nov 10, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
9
Price at Filing: $93.18
Real-time Price: $96.13 info
Change: +$2.95 (+3%) info
Market Cap: $6.276B info
MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $96.13 info
Change: +$9.10 (+10%) info
Market Cap: $6.276B info
MIRM
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $96.13 info
Change: +$9.10 (+10%) info
Market Cap: $6.276B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $96.13 info
Change: +$15.98 (+20%) info
Market Cap: $6.276B info